Sort   by:  
 Page size 
UnknownImpact of prior flavivirus immunity on Zika virus infection in rhesus macaques.
Studies have demonstrated cross-reactivity of anti-dengue virus (DENV) antibodies in human sera against Zika virus (ZIKV), promoting increased ZIKV infection in vitro. However, the correlation between in vitro and in vivo findings is not well characterized. Thus, we evaluated the impact of heterotyp...
S-EPMC5542404 | biostudies-literature
UnknownZika-specific neutralizing antibodies targeting inter-dimer envelope epitopes.
Zika virus (ZIKV) is an emerging pathogen that causes devastating congenital defects. The overlapping epidemiology and immunologic cross-reactivity between ZIKV and dengue virus (DENV) pose complex challenges to vaccine design, given the potential for antibody-dependent enhancement of disease. There...
S-EPMC10775418 | biostudies-literature
UnknownPotent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.
Zika virus (ZIKV) has caused significant disease, with widespread cases of neurological pathology and congenital neurologic defects. Rapid vaccine development has led to a number of candidates capable of eliciting potent ZIKV-neutralizing antibodies (reviewed in refs. 1-3). Despite advanc...
S-EPMC7018608 | biostudies-literature
UnknownEffect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.

Importance

The evidence for benefit of convalescent plasma for critically ill patients with COVID-19 is inconclusive.

Objective

To determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19.

Design, setting, and participants

The ongoing...
S-EPMC8491132 | biostudies-literature
UnknownSimvastatin in Critically Ill Patients with Covid-19.

Background

The efficacy of simvastatin in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.

Methods

In an ongoing international, multifactorial, adaptive platform, randomized, controlled trial, we evaluated simvastatin (80 mg daily) as compared with no stati...
S-EPMC10755839 | biostudies-literature
UnknownEffect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.

Importance

Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19.

Objective

To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patien...
S-EPMC10326520 | biostudies-literature
UnknownIntravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials.

Importance

The efficacy of vitamin C for hospitalized patients with COVID-19 is uncertain.

Objective

To determine whether vitamin C improves outcomes for patients with COVID-19.

Design, setting, and participants

Two prospectively harmonized randomized clinical trials enrolled c...
S-EPMC10600726 | biostudies-literature
UnknownEffect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.

Importance

The efficacy of antiplatelet therapy in critically ill patients with COVID-19 is uncertain.

Objective

To determine whether antiplatelet therapy improves outcomes for critically ill adults with COVID-19.

Design, setting, and participants

In an ongoing adaptive platfor...
S-EPMC8941448 | biostudies-literature
UnknownLong-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.

Importance

The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown.

Objective

To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes.

Design, setting, and participants

S-EPMC9857594 | biostudies-literature
Sort   by:  
 Page size